Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kanglao Gujin Granules is a Traditional Chinese Medicine (TCM) herbal formulation primarily utilized as an adjuvant therapy for pulmonary tuberculosis (PTB). Developed as a hospital preparation by the Beijing Chest Hospital, it is specifically indicated for patients exhibiting the "Lung-Kidney Yin Deficiency" pattern, characterized by symptoms such as chronic cough, night sweats, and hemoptysis. The formulation consists of several botanical ingredients, including *Glehnia littoralis*, *Rehmannia glutinosa*, and *Ophiopogon japonicus*, which are traditionally believed to nourish Yin and moisten the lungs. In clinical settings, it is typically administered alongside standard first-line anti-tuberculosis chemotherapy (HRZE regimen) to improve clinical efficacy, accelerate the absorption of pulmonary lesions, and potentially reduce the adverse effects associated with long-term synthetic antibiotic use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kanglao Gujin Granules.